Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model

International Journal of Pharmaceutics

Volumn 445, Issue 1-2, 2013, Pages 171-180

  Roy, Aniruddha ^a   Singh, Manu Smriti ^a   Upadhyay, Pramod ^a   Bhaskar, Sangeeta ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Chemo immunotherapy; Nanoparticle; Paclitaxel; TLR 4 agonist; Tumor immune stimulation

Indexed keywords

NANOPARTICLE; PACLITAXEL; POLYGLACTIN; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; LACTIC ACID; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; PACLITAXEL; POLYGLYCOLIC ACID; TOLL-LIKE RECEPTOR 4; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84874941640     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.01.045     Document Type: Article

References (30)

1. P. Allavena, and A. Mantovani Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment Clin. Exp. Immunol. 167 2012 195 205
2. F. Danhier, N. Lecouturier, B. Vroman, C. Jerome, J. Marchand-Brynaert, O. Feron, and V. Preat Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation J. Control Release 133 2009 11 17
3. M.B. Davis, D. Vasquez-Dunddel, J. Fu, E. Albesiano, D. Pardoll, and Y.J. Kim Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses Clin. Cancer Res. 17 2011 3984 3992
4. L.A. Emens Chemoimmunotherapy Cancer J. 16 2010 295 303
5. R.P. Garay, P. Viens, J. Bauer, G. Normier, M. Bardou, J.F. Jeannin, and C. Chiavaroli Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help Eur. J. Pharmacol. 563 2007 1 17
6. A.S. Giermasz, J.A. Urban, Y. Nakamura, P. Watchmaker, R.L. Cumberland, W. Gooding, and P. Kalinski Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines Cancer Immunol. Immunother. 58 2009 1329 1336
7. S. Gordon Alternative activation of macrophages Nat. Rev. Immunol. 3 2003 23 35
8. T. Hagemann, T. Lawrence, I. McNeish, K.A. Charles, H. Kulbe, R.G. Thompson, S.C. Robinson, and F.R. Balkwill "Re-educating" tumor-associated macrophages by targeting NF-kappaB J. Exp. Med. 205 2008 1261 1268
9. S. Hallam, M. Escorcio-Correia, R. Soper, A. Schultheiss, and T. Hagemann Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB J. Pathol. 219 2009 143 152
10. J.R. Hsiao, S.F. Leu, and B.M. Huang Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines J. Oral Pathol. Med. 38 2009 188 197
11. C.M. Hu, and L. Zhang Nanoparticle-based combination therapy toward overcoming drug resistance in cancer Biochem. Pharmacol. 83 2012 1104 1111
12. I.D. Jung, S.K. Jeong, C.M. Lee, K.T. Noh, D.R. Heo, Y.K. Shin, C.H. Yun, W.J. Koh, S. Akira, J. Whang, H.J. Kim, W.S. Park, S.J. Shin, and Y.M. Park Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist Cancer Res. 71 2011 2858 2870
13. J. Kohlmeyer, M. Cron, J. Landsberg, T. Bald, M. Renn, S. Mikus, S. Bondong, D. Wikasari, E. Gaffal, G. Hartmann, and T. Tuting Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy Cancer Res. 69 2009 6265 6274
14. N. Leffers, M.J. Gooden, R.A. de Jong, B.N. Hoogeboom, K.A. ten Hoor, H. Hollema, H.M. Boezen, A.G. van der Zee, T. Daemen, and H.W. Nijman Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol. Immunother. 58 2009 449 459
15. Y.S. Lin, L.D. Huang, C.H. Lin, P.H. Huang, Y.J. Chen, F.H. Wong, C.C. Lin, and S.L. Fu In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator J. Biol. Chem. 286 2011 43782 43784
16. J.I. Lundin, and H. Checkoway Endotoxin and cancer Environ. Health Perspect. 117 2009 1344 1350
17. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati The chemokine system in diverse forms of macrophage activation and polarization Trends Immunol. 25 2004 677 686
18. I. Marigo, L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells Immunol. Rev. 222 2008 162 179
19. G. Morgan, R. Ward, and M. Barton The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies Clin. Oncol. (R. Coll. Radiol.) 16 2004 549 560
20. F. Pages, J. Galon, M.C. Dieu-Nosjean, E. Tartour, C. Sautes-Fridman, and W.H. Fridman Immune infiltration in human tumors: a prognostic factor that should not be ignored Oncogene 29 2010 1093 1102
21. A. Roy, M.S. Singh, P. Upadhyay, and S. Bhaskar Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach Mol. Pharm. 7 2010 1778 1788
22. J.R. Schenck, M.P. Hargie, M.S. Brown, D.S. Ebert, A.L. Yoo, and F.C. McIntire The enhancement of antibody formation by Escherichia coli lipopolysaccharide and detoxified derivatives J. Immunol. 102 1969 1411 1422
23. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
24. S. Shah, R. Raghupathy, O. Singh, G.P. Talwar, and A. Sodhi Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine Vaccine 17 1999 3116 3123
25. S. Singh, and A.K. Dash Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges Crit. Rev. Ther. Drug Carrier Syst. 26 2009 333 372
26. J. Szebeni, F.M. Muggia, and C.R. Alving Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study J. Natl. Cancer Inst. 90 1998 300 306
27. B. Wang, Q. Li, L. Qin, S. Zhao, J. Wang, and X. Chen Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice BMC Immunol. 12 2011 43
28. S. Wang, I.A. Astsaturov, C.A. Bingham, K.M. McCarthy, M.M. von, W. Xu, R.K. Alpaugh, Y. Tang, B.A. Littlefield, L.D. Hawkins, S.T. Ishizaka, and L.M. Weiner Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment Cancer Immunol. Immunother. 61 2012 49 61
29. H. Zhong, B. Han, I.L. Tourkova, A. Lokshin, A. Rosenbloom, M.R. Shurin, and G.V. Shurin Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth Clin. Cancer Res. 13 2007 5455 5462
30. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer Immunological aspects of cancer chemotherapy Nat. Rev. Immunol. 8 2008 59 73